Bare Metal Bifurcation Stent Clinical Trial in Humans

NCT ID: NCT00607321

Last Updated: 2017-05-18

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 60 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2008-02-29
• Study Completion Date: 2010-08-31

Brief Summary

To assess the feasibility and safety of the Medtronic Bifurcation Stent System for the treatment of single de novo bifurcation lesions in native coronary arteries with reference vessel diameters (RVD) for the proximal main vessel of 3.8 - 4.3 mm, distal main branch of 3.0 - 3.5 mm, and side branch RVD up to 2.5 mm.

Conditions

Coronary Artery Disease; Myocardial Ischemia

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

1

Medtronic Bifurcation Stent System

Group Type: EXPERIMENTAL

Medtronic Bifurcation Stent System

Intervention Type: DEVICE

Percutaneous Coronary Stenting

Interventions

Medtronic Bifurcation Stent System

Percutaneous Coronary Stenting

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

• Candidate for percutaneous coronary intervention & emergent coronary artery bypass graft surgery
• Clinical evidence of ischemic heart disease or a positive functional study
• Female patients of childbearing potential has negative pregnancy test within 7 days before trial procedure
• Patient or patient's legal representative provided written informed consent
• Patient agrees to comply with follow-up evaluations

• Target lesion ia a single de novo bifurcation lesion involving a native coronary artery with reference vessel diameter for the proximal main of 3.8 - 4.3 mm, distal main of 3.0 - 3.5 mm, & side branch RVD up to 2.5 mm
• Acceptable target lesion lengths are any combination of:
• <16mm proximally from carina in proximal main vessel
• <16mm distally from the carina in distal main branch
• <12mm from carina in side branch
• Target lesion in main vessel has stenosis of > 50% and <100%
• Target vessel has (TIMI) flow >2

Exclusion Criteria

• Known hypersensitivity/contraindication to aspirin, heparin or bivalirudin, clopidogrel or ticlopidine, cobalt, nickel, chromium, molybdenum, or sensitivity to contrast media, which can't be adequately pre-medicated
• Platelet count <100,000 cells/mm³ or >700,000 cells/mm³, or a white blood cell (WBC) count <3,000 cells/mm³ within 7 days prior to index procedure
• Serum creatinine level >170 micromol/L within 7 days prior to index procedure
• Evidence of acute MI within 72 hours of intended trial procedure (defined as: QWMI or NQWMI having CK enzymes >2X laboratory upper limit of normal with presence of elevated CK-MB (any amount above laboratory upper limit of normal)
• Previous stenting anywhere in target vessel
• PCI of non-target vessel within 30 days prior to procedure that results in any MACE event. If non target vessel stent is implanted within 72 hours prior to index procedure, 2 post procedural serial CK or CK-MB measurements must be below investigational site's upper limit of normal.
• PCI of non-target vessel within 24 hours prior to procedure
• Planned PCI of any vessel within 30 days post-procedure
• Planned PCI of the target vessel within 6 months post-procedure
• During index procedure, target lesion requires treatment with device other than PTCA or cutting balloon prior to stent placement
• Documented left ventricular ejection fraction (LVEF) <30% at most recent evaluation.
• History of stroke or transient ischemic attack (TIA) within prior 6 months
• Active peptic ulcer or upper gastrointestinal (GI) bleeding within prior 6 months
• History of bleeding diathesis or coagulopathy or will refuse blood transfusions
• Concurrent medical condition with life expectancy < 12 months
• Currently participating in investigational drug or device trial that's not completed the primary endpoint or that clinically interferes with current trial endpoints; or requires coronary angiography, IVUS or other coronary artery imaging procedures.

• Bifurcation angle of >90 degrees by visual estimate
• Target lesion located in native vessel with saphenous vein graft or left/right internal mammary artery (LIMA/RIMA) bypass
• Significant stenosis (>50%) proximal or distal to target lesion that might require revascularization or impede run off.
• Target vessel is excessively tortuous (two bends >90º to reach target lesion)
• Target lesion has any of following characteristics:
• Lesion location is aorto-ostial, unprotected left main lesion, or within 5 mm of origin of left anterior descending (LAD), left circumflex (LCX), or right coronary artery (RCA).
• Severely calcified
• Evidence of thrombus
• Co-existence of unprotected left main coronary artery disease (obstruction >50% in left main coronary artery)

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Medtronic Vascular

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Ian Meredith, MD

Role: PRINCIPAL_INVESTIGATOR

Monash Medical Centre

Locations

Auckland City Hospital

Auckland, , New Zealand

Countries

New Zealand

Other Identifiers

IP088

Identifier Type: -

Identifier Source: org_study_id